Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
To learn more about trials that might be of interest to you, please contact us and an IND representative will be in touch to discuss your options.
Study Open - Currently Enrolling
The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort.
Study Open - Currently Enrolling
Longitudinal evaluation of [18F] AV-133 as a PET radioligand for detecting disease progression in patients with Parkinson disease.
Study Open - Currently Enrolling
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease
Study Open - Currently Enrolling
A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson’s Disease.
Study Open - Currently Enrolling
The Assessment of Brain Tau Burden in Participants with Parkinson's Disease in the PPMI Study (PPMI Tau PET Imaging) will evaluate if [18F] PI-2620 facilitates better understanding of Tau deposition in the brain in Parkinson's disease (PD).
Study Open - Recruitment Closed
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson’s Disease with a 52 Week Blinded Extension (Pasadena)
Study Open - Currently Enrolling
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
Study Open - Currently Enrolling
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Diseas
Study Open - Enrolling by invitation
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Study Open - Recruitment Closed
A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy, and safety study of MTAU9937A in patients with moderate Alzheimer’s Disease.
To learn more about trials that might be of interest to you, please contact us and an IND representative will be in touch to discuss your options.
Currently Enrolling
The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study sponsored by the Michael J Fox Foundation to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls
Currently Enrolling
Many of the symptoms in Alzheimer disease and Parkinson disease relate to changes in specific neurochemicals in the brain. The imaging research program at IND is developing techniques to all for imaging these neurochemical changes. Healthy volunteers are critical to this research as it is necessary to compare the changes in the brain that occur with the brain of healthy individuals.
www.ClinicalTrials.gov is a government sponsored website which provides listings of clinical research studies for all diseases, and gives contact information. You can find the most update-to-date information on IND studies using the link below.
Institute for Neurodegenerative Disorders
55 Church Street, 7th Floor, New Haven, Connecticut 06510, United States
Copyright © 2024 IND - All Rights Reserved.